CA2307890A1 - Hesperidine et hesperetine en tant qu'inhibiteur d'acyle coa-cholesterol-o-acyltransferase, inhibiteur de l'accumulation du complexe macrophages-lipides sur la paroi arterielle etagent prophylactique ou therapeutique de maladies hepatiques - Google Patents

Hesperidine et hesperetine en tant qu'inhibiteur d'acyle coa-cholesterol-o-acyltransferase, inhibiteur de l'accumulation du complexe macrophages-lipides sur la paroi arterielle etagent prophylactique ou therapeutique de maladies hepatiques Download PDF

Info

Publication number
CA2307890A1
CA2307890A1 CA002307890A CA2307890A CA2307890A1 CA 2307890 A1 CA2307890 A1 CA 2307890A1 CA 002307890 A CA002307890 A CA 002307890A CA 2307890 A CA2307890 A CA 2307890A CA 2307890 A1 CA2307890 A1 CA 2307890A1
Authority
CA
Canada
Prior art keywords
hesperidin
hesperetin
composition
cholesterol
mammal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002307890A
Other languages
English (en)
Inventor
Jun-Sung Lee
Kwang-Hee Son
Yang-Kyu Choi
Byung-Hwa Hyun
Chul-Ho Lee
Ki-Hwan Bae
Eun-Sook Lee
Yong-Bok Park
Hyo-Soo Kim
Myung-Sook Choi
Ingyu Hwang
Jung-Ah Ahn
Tae-Sook Jeong
Sung-Uk Kim
Doil Choi
Surk-Sik Moon
Yong-Kook Kwon
Young-Kook Kim
Young-Bae Park
Seong-Choon Choe
Song-Hae Bok
Byoung-Mog Kwon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Korea Institute of Science and Technology KIST
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1019970055578A external-priority patent/KR19990034089A/ko
Priority claimed from KR1019980010888A external-priority patent/KR19990076178A/ko
Priority claimed from KR1019980012411A external-priority patent/KR19990079683A/ko
Priority claimed from KR1019980013283A external-priority patent/KR19990080214A/ko
Application filed by Individual filed Critical Individual
Publication of CA2307890A1 publication Critical patent/CA2307890A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/52—Adding ingredients
    • A23L2/56—Flavouring or bittering agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dairy Products (AREA)
  • Confectionery (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Bakery Products And Manufacturing Methods Therefor (AREA)
  • Meat, Egg Or Seafood Products (AREA)
  • Seasonings (AREA)

Abstract

L'invention concerne des utilisations d'hespéridine ou d'hespérétine afin d'inhiber l'activité d'acyle CoA-cholestérol-o-acyltransférase, d'inhiber l'accumulation du complexe constitué par des macrophages et des lipides sur l'endothélium artériel et d'exercer une action prophylactique ou thérapeutique sur des maladies hépatiques chez le mammifère.
CA002307890A 1997-10-28 1998-10-20 Hesperidine et hesperetine en tant qu'inhibiteur d'acyle coa-cholesterol-o-acyltransferase, inhibiteur de l'accumulation du complexe macrophages-lipides sur la paroi arterielle etagent prophylactique ou therapeutique de maladies hepatiques Abandoned CA2307890A1 (fr)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
KR1997/55578 1997-10-28
KR1019970055578A KR19990034089A (ko) 1997-10-28 1997-10-28 헤스페리딘또는헤스페레틴을포함하는아실코에이:콜레스테롤-오르토-아실트랜스퍼레이즈 저해제조성물
KR1019980010888A KR19990076178A (ko) 1998-03-28 1998-03-28 헤스페리딘을 포함하는 간 질환의 예방 및 치료용 조성물
KR1998/10888 1998-03-28
KR1998/12411 1998-04-08
KR1019980012411A KR19990079683A (ko) 1998-04-08 1998-04-08 감귤류의 과피 분말 또는 과피 추출물을 포함하는 기능성 건강식품
KR1019980013283A KR19990080214A (ko) 1998-04-14 1998-04-14 감귤류의 과피 추출물을 포함하는 건강개선용 기능성 음료
KR1998/13283 1998-04-14
PCT/KR1998/000324 WO1999021549A1 (fr) 1997-10-28 1998-10-20 Hesperidine et hesperetine en tant qu'inhibiteur d'acyle coa-cholesterol-o-acyltransferase, inhibiteur de l'accumulation du complexe macrophages-lipides sur la paroi arterielle et agent prophylactique ou therapeutique de maladies hepatiques

Publications (1)

Publication Number Publication Date
CA2307890A1 true CA2307890A1 (fr) 1999-05-06

Family

ID=27483239

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002307890A Abandoned CA2307890A1 (fr) 1997-10-28 1998-10-20 Hesperidine et hesperetine en tant qu'inhibiteur d'acyle coa-cholesterol-o-acyltransferase, inhibiteur de l'accumulation du complexe macrophages-lipides sur la paroi arterielle etagent prophylactique ou therapeutique de maladies hepatiques

Country Status (5)

Country Link
EP (1) EP1063988A1 (fr)
JP (1) JP2001520993A (fr)
CN (1) CN1124133C (fr)
CA (1) CA2307890A1 (fr)
WO (1) WO1999021549A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020006953A1 (en) * 1999-11-05 2002-01-17 Carla R. McGill Modification of cholesterol concentrations with citus phytochemicals
FR2841472B1 (fr) 2002-06-28 2006-02-24 Agronomique Inst Nat Rech Composition nutritionnelle ou therapeutique contenant le compose hesperidine ou l'un de ses derives
EP1792974B1 (fr) * 2004-07-23 2017-05-17 Suntory Holdings Limited Matériau trempé dans l´alcool, aliment ou boisson utilisant ce matériau et procédé de production de celui-ci
KR20070095338A (ko) * 2004-12-24 2007-09-28 가부시끼가이샤 하야시바라 세이부쓰 가가꾸 겐꾸조 간기능 개선제
EP2368442B1 (fr) 2005-07-27 2014-12-17 Symrise AG Utilisation d'hespérétine pour améliorer le goût sucré
CN101374424B (zh) 2006-01-23 2013-03-27 三得利控股株式会社 食品或饮料及其制造方法
CN100546576C (zh) * 2006-06-15 2009-10-07 安徽医科大学 橙皮素衍生物在制备抗炎免疫药物中的应用
JP2007112806A (ja) * 2006-11-27 2007-05-10 Kao Corp 体脂肪燃焼促進剤
JP2009007256A (ja) * 2007-06-26 2009-01-15 Kao Corp Ｎａｄｈ／ｎａｄｐｈオキシダーゼ抑制剤
CN104688756A (zh) * 2013-12-09 2015-06-10 中国药科大学 一种药物组合物及其在制备治疗酒精性肝损伤药物中的应用
TWI715172B (zh) * 2019-08-28 2021-01-01 健茂生物科技股份有限公司 具有抑制體脂肪形成之組合物
CN114832041A (zh) * 2021-02-01 2022-08-02 健茂生物科技股份有限公司 具有护肝效果的组合物及其制备方法
CN114832007A (zh) * 2021-02-01 2022-08-02 健茂生物科技股份有限公司 降低胆固醇的组合物及其制备方法
CN115607538A (zh) * 2022-09-26 2023-01-17 浙江工商大学 橙皮素在制备抑制和/或治疗小麦过敏的药物中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4150038A (en) * 1977-05-16 1979-04-17 Dynapol Conversion of hesperidin into hesperetin
JPS54154569A (en) * 1978-05-20 1979-12-05 Lotte Co Ltd Chewing gum for sports
ATE87204T1 (de) * 1987-12-10 1993-04-15 Tsumura & Co Anti-retrovirales arzneimittel.
MC2041A1 (fr) * 1988-06-24 1990-05-30 Johannes Cornelius Str Andries Agents anti-atherogenic
JPH04295428A (ja) * 1991-03-22 1992-10-20 Dai Ichi Seiyaku Co Ltd 抗アレルギー剤
AU6666594A (en) * 1993-04-20 1994-11-08 Procter & Gamble Company, The Methods of using hesperetin for sebum control and treatment of acne
JPH0725761A (ja) * 1993-07-09 1995-01-27 Kureha Chem Ind Co Ltd 軟骨保護剤
JP3557711B2 (ja) * 1995-04-12 2004-08-25 日本新薬株式会社 脂質代謝改善に有効な食品及び製法
JPH08283154A (ja) * 1995-04-12 1996-10-29 Nippon Shinyaku Co Ltd 脂質代謝改善剤

Also Published As

Publication number Publication date
CN1124133C (zh) 2003-10-15
WO1999021549A1 (fr) 1999-05-06
CN1278170A (zh) 2000-12-27
JP2001520993A (ja) 2001-11-06
EP1063988A1 (fr) 2001-01-03

Similar Documents

Publication Publication Date Title
US6165984A (en) Naringin and naringenin as inhibitors of acyl CoA-cholesterol-o-acyltransferase
CA2307553C (fr) Extrait d'ecorce d'agrumes en tant qu'inhibiteur d'acyle coa-cholesterol-o-acyltransferase, inhibiteur de l'accumulation du complexe macrophage-lipide sur les parois arterielles et agent de prevention ou de traitement des maladies hepatiques
US6509372B2 (en) Method for preventing or treating elevated blood lipid level-related diseases by administering rutin and quercetin
US6133241A (en) Bioflavonoids as plasma high density lipoprotein level increasing agent
RU2203050C2 (ru) Биофлавоноиды в качестве агента, снижающего уровень глюкозы в крови
EP0930889B1 (fr) EXTRAIT D'ECORCE DE CITRUS UTILISE EN TANT QU'INHIBITEUR DE 3-HYDROXY-3-METHYL-GLUTARYL COENZYME A (HMG CoA) REDUCTASE
US20040132816A1 (en) Lipid metabolism and fructus crataegus
CA2307890A1 (fr) Hesperidine et hesperetine en tant qu'inhibiteur d'acyle coa-cholesterol-o-acyltransferase, inhibiteur de l'accumulation du complexe macrophages-lipides sur la paroi arterielle etagent prophylactique ou therapeutique de maladies hepatiques
US20010002264A1 (en) Citrus peel extract as inhibitor of fatty streak formation on the arterial wall
EP1113726B1 (fr) Utilisation de neohesperidine dihydrochalcone dans la preparation d'un medicament pour la prevention ou le traitement de maladies liees a des niveaux eleves de lipide dans le sang
RU2197239C2 (ru) Гесперидин и гесперетин в качестве ингибитора ацил соа-холестерин-о-ацилтрансферазы, ингибиторов накопления комплексов макрофаг-липид на стенках артерий, и в качестве средства для профилактики или лечения заболеваний печени
RU2201228C2 (ru) Нарингин и нарингенин в качестве средства для профилактики или лечения заболеваний печени
EP1123096A1 (fr) Flavonoides utilises comme agents augmentant la teneur en lipoproteines de haute densite du plasma

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead